Full Press Release Details
Key Components for Full Commercialization in 2015 Copyright 2015 Trovagene, Inc. | Confidential 34 Full Commercialization (2015) Drive Adoption of Expanded Menu Conversion of Research Collaborators to Clinical Adopters Expand New Market Segments New Market for Genomic Monitoring Direct sales team 6 sales reps in Phase 1 Headcount ramp to be initiated in Q1 2015 Direct coverage of top target sites Major academic cancer centers Entire ECD/LCH treating physician base IDNs where TROV has relationships Geographic focus on key oncology markets Reimbursement Value Based on Clinical Utilities of ctDNA Copyright 2015 Trovagene, Inc. | Confidential 35 Detection of Mutation Monitoring Tumor Size When tissue biopsy is unavailable Tumor load Emergence of resistant mutations Drug holidays Tier 1 MDx Codes Concordance with SOC Established codes Price/assay Repeat Testing: Novel Utility Not Otherwise Classified Codes (NOC) Unique CPT Codes Once Clinical Data Established, Reimbursement: Supplement tissue biopsy to get systemic overview of the entire heterogeneity of cancer Trovagene Urine-based High Risk HPV Assay Copyright 2015 Trovagene, Inc. | Confidential 36 Urine-based High Risk HPV Assay established in Trovagene s CLIA lab since 2013 265K Deaths in 2012 Market in 2013 $9B Market in 2020 HPV Testing Market Globally Screening is a viable solution: 75% reduction in incidence in US from 1940 to 1980 w/ National Screening Program Screening not available globally: Cost, Technical expertise, Healthcare infrastructure, Quality Control, Cultural High-risk HPVs cause virtually all cervical cancers New Clinical Evidence Queen Mary, UL: High sensitivity of test for detecting HPV associated with CIN2+, CIN3 (malignancy) NCI: Comparative Urine Study J Clin Virol. 2014 Aug;60(4):414-7 UNC: Urine collection methodology for detecting HPV associated with CIN2+/CIN3 Cervical Cancer Source: Transparency Market Research Developing Trovagene s HPV Franchise Internal Development Clinical studies in general screening population Strand Life Sciences (3,000 patients, enrollment underway) Planning stages for pivotal studies Obtain regulatory compliance Copyright 2015 Trovagene, Inc. | Confidential 37 Partnering Opportunities Strategic partners to commercialize the test globally CE Mark FDA Catalysts & Milestones to Drive Valuation Copyright 2015 Trovagene, Inc. | Confidential 38 Demonstrate clinical utility Expand mutation coverage on PCM platform Initiate new collaborations to establish clinical utility Establish strategic partnerships to grow market reach Drive early adoption in top cancer centers and integrated healthcare networks 20+ abstracts and manuscripts in 2015 8 New Menu Assays 10+ clinical studies in 2015 Top academic centers Geographic expansion Kit manufacturing Pharma collaboration HPV collaboration Commercial presence in 20 cancer centers with repeat revenue For further information Please contact: Stephen Zaniboni, CFO szaniboni@trovagene.com Antonius Schuh, CEO aschuh@trovagene.com
Abstract ECD/LCH BRAF MSKCC/MDACC Submit manuscript HR-HPV Method Submit manuscript HR-HPV Predictor4 11/2014 10/2014 Market Development Activities for Commercialization Program Copyright 2015 Trovagene, Inc. | Confidential 33 Market Development (2013-2014) Full Commercialization (2015) Target KOLs/ Early adopters Develop IIS (Investigator Initiated Study) Program Accelerate Adoption within Integrated Healthcare Delivery Networks (IDNs) Branding, Market Awareness and Education Relationships w/ 30+ top cancer centers 17 National Comprehensive Cancer Network (NCCN) Centers 100+ oncologists engaged in outreach Signed partnership w/ 2 major IDNs CHI (Catholic Health Initiative) 105 hospitals Lurie Cancer Center of Northwestern Univ.
Submit abstracts Q4 Q1 Q2 Q3 3/2015 10/2015 Submit manuscript Longitudinal and pharmacodynamic BRAF and KRAS multiple cancers MD Anderson ASCO Submit abstracts Melanoma, lung, pancreatic colorectal cancers AACR 3 abstracts submitted IPV Conference Submit Abstracts 4/2015 5/2015 8/2015 9/2015 Submit manuscript Longitudinal KRAS Colorectal Submit manuscript Longitudinal KRAS Pancreatic ASCO GI 2 abstracts accepted 1/2015 NEXTGEN DX SUMMIT Submit abstract Technology Submit manuscript KRAS/BRAF colorectal Technology comparison study EUROGIN Oral presentation 2/2015 16th World Conference on Lung Cancer Submit abstracts 9/2015 European Lung Cancer Conference Oral presentation 4/2015 Chicago Multidisciplinary Symposium in Thoracic Oncology Submit abstracts 10/2015 ESMO Submit abstracts 9/2015 Q4 Q4 2015 Submit manuscript Detection and monitoring EGFR T790M Lung EORTC-NCI-AACR Abstract(s) HISTIOCYTIC SOC.
CA19-9 Pancreatic/USOR-SH-UCSF 45 BRAF ctDNA avoids immunotherapy pseudo-progression Melanoma/DFCI 40 EGFR T790M Predict initial/clinical response of new therapeutic Lung/Pharma 375 KRAS Correlate ctDNA to Tx response/PD/recurrence Colorectal/GRI 54 KRAS Correlate ctDNA to Tx response/PD/recurrence Pancreatic/Univ. Copenhagen 1000 EGFR Non-responders to EGFR activating mutations to Tx Lung/Catholic Health Initiatives 30 CRC and others/ONG-INB KRAS/BRAF Monitor tumor dynamics and acquired resistance 40 Lung/UCSD EGFR ctDNA assessment as a biomarker 500 EGFR Longitudinal cfDNA EGFR mutational analysis Lung/City of Hope 75 Ongoing Clinical Studies Continue to Drive Publications Copyright 2015 Trovagene, Inc. | Confidential 32 2014 EORTC-NCI-AACR Submit abstracts HISTIOCYTIC SOC.
Tissue Biopsy Concordant KRAS mutation at baseline 19/20 evaluable Urine vs. Plasma Concordant KRAS mutation at baseline 12/12 matched Urine vs. Tissue Biopsy Concordant KRAS mutation at baseline 11/12 evaluable 95% 100% 92% Serial monitoring during and post surgery (n=193 plasma and urine samples) 20 Stage IV colorectal cancer patients with resectable liver metastases KRAS mutation in tissue Matched urine and plasma, archived (3-5 years) Blinded analysis, seven KRAS mutations (G12A/C/D/R/S/V and G13D) 1Poole et al, ASCO GI 2015 22 Copyright 2015 Trovagene, Inc. | Confidential High Concordance btw Urine & Plasma ctDNA KRAS in Advanced CRC: Monitoring During & Post Surgery1 Curative surgery correlates with un-detectable levels of ctDNA KRAS post-surgery Palliative surgery correlates with high levels of ctDNA KRAS post-surgery 1Poole et al, ASCO GI 2015 23 Copyright 2015 Trovagene, Inc. | Confidential Monitoring Treatment Response in Resectable and Non-Resectable Advanced Pancreatic Cancer Patients by ctDNA KRAS1 24 182 Patients with Non-Resectable Pancreatic Cancer Chemotherapy Plasma, archived < 6 years 50 Patients with Resectable Pancreatic Cancer Surgery, Chemotherapy Plasma, archived < 6 years 150 Plasma Samples: Pre-operative, Post-Surgery, Serial Collections on Chemotherapy 249 days OS (median) KRAS > 300 copies /100K GE p < 0.0002, HR = 2.44 (95% CI:1.63-3.67) ctDNA KRAS detection at baseline for association with overall survival KRAS < 6 copies/100K GE 136 days OS (median) ctDNA KRAS monitoring for response to chemotherapy ctDNA KRAS detection at baseline for association with overall survival ctDNA KRAS monitoring for response to chemotherapy 640 Plasma Samples: Baseline, Serial Collections on Chemotherapy 214 days OS (median) KRAS 6 - 300 copies/100K GE p < 0.0002, HR = 2.06 (95% CI:1.41-3.00) 1Johansen et al, ASCO GI 2015 Copyright 2015 Trovagene, Inc. | Confidential Monitoring ctBRAF V600E and Treatment Response1 25 17 metastatic cancer patients 15 evaluable patients for ctDNA BRAF V600E >4 weeks Evaluate time to progression % tumor change per RECIST 1.1 Urine ctDNA BRAF decrease Urine ctDNA BRAF increase Urine BRAF ctDNA correlates to BRAF/MEK targeted therapy (p=0.002) Urine BRAF V600E ctDNA monitoring has clinical utility to track therapeutic efficacy of targeted therapy in metastatic cancer patients harboring mutant BRAF V600E Positive urine BRAF V600E 259 days (median) to progression 95% CI=240-278 days 61 days (median) to progression 95% CI = 59-63 days p=0.002 1Janku et al, AACR 2014 Copyright 2015 Trovagene, Inc. | Confidential Patient 5: Metastatic Melanoma Patient 36: Metastatic Non-Small Cell Lung Cancer Longitudinal ctDNA BRAF V600E Mutation Status Correlates with Therapy Response1 26 Patient 8: Metastatic Non-Small Cell Lung Cancer Patient 16: Metastatic Colorectal Cancer Urine BRAF V600E ctDNA monitoring has clinical utility to track therapeutic efficacy of targeted therapy in metastatic cancer patients 1Janku et al, AACR 2014 Copyright 2015 Trovagene, Inc. | Confidential NSCLC Standard of Care 27 Monitoring Emergency of Resistance EGFR T790M Monitoring Tumor Burden EGFR T790M Monitoring Tumor Burden EGFR Exon 19 Deletion EGFR L858R Detection EGFR Exon 19 Deletion EGFR L858R TROVAGENE Copyright 2015 Trovagene, Inc. | Confidential 28 Biopsy with AE ~20% Claims Biopsy without AE ~80% Claims Average Biopsy Cost While the median cost for a lung cancer biopsy is ~$3,750, a recent review of 5% of the Medicare population found that complications drove average biopsy cost to $14,634. 1Medicare claims analysis presented by Lokhandwala at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology mtg NSCLC Initial Biopsy: Cost Assumptions1 Copyright 2015 Trovagene, Inc. | Confidential Replacing Tissue Biopsy in Metastatic NSCLC with ctDNA Monitoring ctDNA EGFR for Treatment Response and Early Acquisition of EGFR T790M 30 Metastatic NSCLC Patients, Exploratory 3rd Generation TKIs 300 Metastatic NSCLC Patients at Diagnosis, EGFR Exons19 and 21 Status in Tissue ctDNA Monitoring for Response and Early Acquisition of EGFR T790M 210 Urine Samples Daily Collections Week 1 on 3rd Generation TKIs 100 Metastatic NSCLC Patients, 1st Line anti-EGFR Therapy 600 Urine Samples Serial Collections on Erlotinib Evaluate EGFR Concordance between Urine and Tissue Evaluate EGFR Concordance between Plasma and Tissue 300 Matched Urine and Plasma Samples ctDNA EGFR T790M Monitoring for Early Response Multi-Institutional Program EGFR T790M Concordance between Urine and Tissue Urine vs Tissue Concordant EGFR T790M Mutation at Baseline 6/6 Patients 100% Copyright 2015 Trovagene, Inc. | Confidential 29 Current Development Program for Cancer Monitoring Applications Copyright 2015 Trovagene, Inc. | Confidential 30 KRAS Exon 2 BRAF V600E KRAS Exon 2,3,4 NRAS Exon 2,3,4 BRAF V600E PIK3CA H1047R EGFR Exon 20 T790M EGFR Exon 19 Del EGFR Exon 21 L858R ALK Rearrangements NRAS Exon 2 Ongoing Clinical Utility Studies Copyright 2015 Trovagene, Inc. | Confidential 31 Detection of Mutation Monitoring Tumor Load Emergence of Resistant Mutations Pancreatic/MDACC Brain/UCSD Lung/MSKCC KRAS BRAF EGFR Minimal residual disease detection post surgery Detect ctDNA in brain cancer patients Detection and monitoring of EGFR mutations Colorectal/USC Lung/MSKCC KRAS EGFR T790M Emergence of mutant KRAS on anti-EGFR Tx T790M detection prior to radiological progression Cancer Type/Institution Biomarker Clinical Utility Examined 90 5 200 60 25 # Patients Expected BRAF/KRAS Faster assessment of therapeutic efficacy All Comers/MDACC 185 KRAS Monitor disease burden by ctDNA vs.
BRAFV600E allele burden in urine changes dynamically with therapy. 1Hyman et al., Cancer Discov. 2015 Jan;5(1):64-71 Copyright 2015 Trovagene, Inc. | Confidential Dynamic Monitoring Captures Early Progression and Response1 Copyright 2015 Trovagene, Inc. | Confidential 21 One week Successful monitoring tumor dynamics independent of drug class used Patient s tumor progressed within 1 wk of Anakinra withdrawal Demonstration of need for higher frequency urine-based testing to monitor Patient responded to Vemurafenib, BRAF inhibitor Demonstrates that continually monitoring patient enables optimal therapy over time 1Hyman et al., Cancer Discov. 2015 Jan;5(1):64-71 Detection and Monitoring Minimal Residual Disease in Surgical Colorectal Cancer Patients with Liver Metastases1 Urine (20 Patients) Plasma (20 Patients) Plasma vs.
(# of pts) Lung Cancer (NSCLC) 8 1 399,000 Colorectal Cancer 4 3 1,154,000 Pancreatic Cancer 3 1 42,000 Melanoma 2 4 922.000 ECD/LCH 2 1 5,000 Brain Cancer 1 1 142,000 Prostate Cancer 1 2,618,000 All-Comers, Metastatic Cancers 2 525,000 HPV 2 3 Total # of Studies 20 12 5 SM Increasing Volume of Clinical Study Samples Received Copyright 2015 Trovagene, Inc. | Confidential 16 Clinical Results Presented & Published To Date Copyright 2015 Trovagene, Inc. | Confidential 17 2014 2 ASCO Presentations Histiocytic BRAF MSKCC/MD Anderson Longitudinal BRAF MD Anderson AACR Poster Concordant BRAF NEXTGEN DX SUMMIT Oral Presentation, Technology IPV Meeting Poster Presentation HR-HPV Publication Cancer Discovery Histiocytic BRAF Q1 Q2 Q3 4/2014 6/2014 8/2014 8/2014 ECD guideline Initial concordance with plasma and tissue Initial longitudinal data concordance with imaging Publication Oncotarget Histiocytic BRAF MD Anderson 5/2014 Publication Blood ECD clinical guidelines 5/2014 10/2014 Q4 Prospective Blinded Study of BRAF V600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders1 18 Histiocytic Patients N=30 Urine cfDNA BRAF V600E V600E Positive V600E Negative Evaluate Tissue Biopsy BRAF V600E Concordance Evaluate Plasma BRAF V600E Concordance Evaluate Tissue Biopsy BRAF WT Concordance Evaluate Plasma BRAF WT Concordance Background Objectives Study Design Erdheim Chester disease (ECD) and Langerhans Cell Histiocytosis (LCH) are histiocytic diseases Histiocytic diseases harbor somatic mutations (i.e., BRAF V600E) Patients with BRAF V600E mutation respond to BRAF inhibitors Histiocytic tissue technically challenging for tissue biopsy Concordance: Tissue biopsy (gold standard) vs. urine BRAF cfDNA Urine vs. plasma BRAF cfDNA Longitudinal: Urine cfDNA BRAF status during treatment regimen Urine and Plasma from patients Blinded study: tissue biopsies (CLIA) correlated after ctDNA results 1Hyman et al., Cancer Discov. 2015 Jan;5(1):64-71 Copyright 2015 Trovagene, Inc. | Confidential ctDNA Improves Genotyping Over Tissue Biopsies in Histiocytic Patients1 19 Urinary ctDNA N=30 Initial Tissue Results Plasma ctDNA N=19 Initial Tissue Results Trovagene Assay Results Trovagene Assay Results Urinary ctDNA BRAFV600E genotype Tissue BRAFV600E genotype Indeterminate Genotype BRAFV600E Mutant BRAF Wildtype n=9 n=6 n=15 BRAFV600E Mutant BRAF Wildtype n=14 n=16 On BRAF inhibitor p=0.005 p=0.02 On BRAF inhibitor 100% concordance between tissue, urine and plasma in treatment naive patients 1Hyman et al., Cancer Discov. 2015 Jan;5(1):64-71 Copyright 2015 Trovagene, Inc. | Confidential Correlation between Longitudinal ctDNA and Radiographic Response1 20 BRAFV600E burden in urine correlates w/ radiographic response.
Ex. BRAF, KRAS $100-$200M Revenue Expand mutational coverage of urine-based actionable oncogene mutations for our PCM platform Clinical Utility: Quantitatively assess mutational status in urine longitudinally as an indicator of responsiveness to therapy, disease status & emergence of resistance mutations Demonstrate in multi-institutional trials that results from urine-based monitoring of actionable mutations increases patient progression-free survival (PFS) & overall survival (OS) Demonstrate health economic benefits of non-invasive oncogene mutation monitoring Clinical Utility: Quantitatively assess patient mutational status in urine longitudinally for mutational status and early detection of resistance to therapy as a decision tool for therapy selection $500+M Revenue Multi $B Revenue QUALITATIVE QUANTITATIVE STANDARD OF CARE Tumor Status Stage 1 Tumor Dynamics Stage 2 Improved Patient Outcomes Stage 3 30+ Collaborations to Validate & Integrate our PCM Platform Copyright 2015 Trovagene, Inc. | Confidential 15 Disease Ongoing Pending Protocol in Dev/Approval Under Evaluation Market Size U.S.
Copyright 2015 Trovagene, Inc. | Confidential 11 Unlimited Volume Urine ctDNA Plasma ctDNA 3,000 15,000 genome equivalent 15,000 150,000 genome equivalent Frequency of Testing Completely Non-invasive Convenient Trovagene Precision Cancer Monitoring (PCM ) Platform Copyright 2015 Trovagene, Inc. | Confidential 12 Ultra-Sensitive Detection and Quantitative Monitoring 100-1000 fold enrichment ~0.5 g ctDNA/ 100 mL of urine Integration with Commercially Available Platforms Single Molecule Detection Proprietary error rate detection and normalization. ctDNA 4.9 ng/ul gDNA 0.04 ng/ul ctDNA 2.0 ng/ul gDNA 1.4 ng/ul Extraction and Isolation of ctDNA Mutant Allele Enrichment Platform Agnostic Detection and Quantification 59% 92% SM Patent Portfolio Copyright 2015 Trovagene, Inc. | Confidential 13 51-110 bp TrNA Family Concentrating Urine Family Patent Term Term to approx. 2035 US provisional app filed Term to approx. 2034 PCT filed Term to approx. 2029 US & EU Term 2018 US & EU Small Footprint Family Monitoring Disease Family 20-50 bp TrNA Family Anion Exchange Purification Family Viral and Pathogen TrNA Families Patent Families TrNA Patent Family Term to approx. 2027 US, EU, Canada Term to approx. 2034 PCT / US nonprovisional app filed Term to approx. 2034 PCT / US nonprovisional app filed Term to approx. 2027 US, EU, Canada Strategy to Drive Clinical Adoption & Reimbursement Copyright 2015 Trovagene, Inc. | Confidential 14 Demonstrate concordance of oncogene mutation status between urine and tumor tissue Clinical Utility: Determine mutational status of actionable biomarkers in urine when a biopsy is not an option.
Cancer is a disease of DNA defining cancer by what tissue it arose in is going to go by the boards pretty soon. Sci Transl Med. 2014 Feb 19;6(224):224ra24. N Engl J Med 2013; 368:1199-1209 Sci. Transl. Med. 4, 136ra68 (2012). Circulating Tumor DNA (ctDNA) Copyright 2015 Trovagene, Inc. | Confidential 10 Tumor cells Main Advantages of ctDNA Captures intratumor heterogeneity Systemic overview of cancer Frequent sampling options for monitoring applications Different analyte options depending on clinical context Why Urine?
Dr. Frances Collins, National Institutes of Health (NIH) Director, Politics on The Frontier of Science , Wall Street Journal, November 8, 2013 Filip Janku M.D., Ph.D et al., 2014 ASCO Annual Meeting Proceedings, a Journal of Clinical Oncology Sarah-Jane Dawson et. al., Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer, NEJM, Vol. 368, No. 12, March 2013 ctDNA Emerging as Preferred Analyte to Monitor Cancer Copyright 2015 Trovagene, Inc. | Confidential 9 Circulating tumor DNA levels showed a greater dynamic range, and greater correlation with changes in tumor burden, than did CA 15-3 or circulating tumor cells.
Peter Hirth, PhD Scientific Advisors Thomas Adams, PhD (Chair) Paul Billings, MD, PhD John P. Brancaccio, CPA Carl B. Feldbaum Gary S. Jacob, PhD Rodney Markin, MD, PhD Antonius Schuh, PhD Stanley Tennant, MD Board of Directors Janel Dockter VP, Product Development Hologic, Gen-Probe, The Scripps Research Institute BA Microbiology David Moskowitz RPh VP, Investor Relations UBS, FBR, Caris & Co, Roth Capital BS Pharmacy | MBA Finance Targeted Therapies for Cancer Therapies are expensive and have side effects Specific for particular biomarkers Response monitoring required Resistance develops Clinical Problem Copyright 2015 Trovagene, Inc. | Confidential 6 Need for Genomic Monitoring Driven by Oncogene mutations and alterations Heterogeneous: Inter-tumor (Distal) New Understanding of Cancer Intra-tumor Limitations of Current Technology for Cancer Monitoring Copyright 2015 Trovagene, Inc. | Confidential 7 Imaging Tissue biopsy Circulating tumor cells Rough indication of tumor size No molecular information Radiation concerns for younger patients Invasive procedures, often not possible Potential for serious complications Serial biopsies increasingly not feasible Not representative of tumor heterogeneity Not representative of tumor heterogeneity Not informative of tumor dynamics Low clinical sensitivity Technically challenging Traditional blood markers Not representative of tumor heterogeneity Non-specific for cancer Low clinical sensitivity Significant Market Opportunity Copyright 2015 Trovagene, Inc. | Confidential 8 $12B In 2010 Insufficient Imaging Tools in Oncology Still Yield Huge Market Initial Opportunity for Trovagene 525K Metastatic cancer patients per year 8-10 Imaging procedures received by cancer patient during first year of treatment $5B Potential market Cancer already in advanced state No molecular data delivered Source: BCC Research The statistically significant correlation between mutational status and treatment response suggests oncogene mutation monitoring using urinary cell-free DNA can help clinicians rapidly determine responders from non-responders, [to] improve patient outcomes.
Chem Oanh Dang PhD VP, Business Development Sequenom, Gen-Probe, Illumina, Sirius Genomics, Zymeworks PhD Biomedical Sciences Stephen Zaniboni Chief Financial Officer Awarepoint, XIFIN, Sorrento Therapeutics, AviaraDx, Arcturus, Sequenom CPA | BS Accounting | MBA Alberto Bardelli, PhD Paul Billings, MD, PhD Charles Cantor, PhD Carlo M. Croce, MD Riccardo Dalla-Favera, MD Brunangelo Falini, MD K.
Copyright 2015 Trovagene, Inc. | Confidential 2 Our Goal To Improve Treatment Outcomes with Copyright 2015 Trovagene, Inc. | Confidential 3 Non-invasive Cancer Monitoring Trovagene s technology non-invasively detects and quantitates circulating tumor DNA in urine and plasma for improved disease management Company Overview Copyright 2015 Trovagene, Inc. | Confidential 4 Numerous clinical collaborations with leading cancer centers 30+ clinical studies Expanding clinical evidence to support broad market adoption Generating health economic data necessary for appropriate reimbursement CLIA certified, CAP accredited, high complexity lab to offer diagnostic services Precision cancer monitoring technology addresses a high unmet clinical need Enables frequent, non-invasive monitoring of oncogene mutation status, disease progression, and recurrence Significant patent portfolio around cell-free DNA Proprietary methods of extracting, purifying, detecting and quantifying oncogene mutations in cell-free DNA NASDAQ: TROV $180M market cap* Molecular Diagnostic Specialist Focused on Cancer Monitoring Founded in 1999 NASDAQ listing 2012 $31M cash on hand (as of 09/30/14) *fully diluted as of 01/08/15 Experienced Leadership Team Copyright 2015 Trovagene, Inc. | Confidential 5 Vlada Melnikova MD, PhD VP, Research & Development Transgenomic, ApoCell, MD Anderson Cancer Center MD | PhD Biological Engineering Mark Erlander PhD Chief Scientific Officer BioTheranostics, AviaraDx, Arcturus, J&J, Scripps Research Institute BS, MS Biochem | PhD Neuroscience Keith McCormick VP, Sales/Mktg BioTheranostics, AviaraDx, Biogen Idec, Schering Plough, Dianon Systems BBA Marketing | MBA Int l Business Antonius Schuh PhD Chief Executive Officer Sorrento Therapeutics, AviaraDx, Arcturus, Sequenom PhD Pharm.
Actual results may differ materially from those projected in the forward-looking statements for various reasons, including risks associated with product and test development, test transfer to contracting labs, government regulation, market acceptance, limited commercial experience, dependence on key personnel, obtaining financing and other factors discussed in the Company's periodic reports filed with the Securities and Exchange Commission.